BEST-MS: A prospective head-to-head comparative study of natalizumab and fingolimod in active relapsing MS. - Cohen M; Mondot L; Bucciarelli F; Pignolet B; Laplaud DA; Wiertlewski S; Brochet B; Ruet A; Defer G; Derache N; Vermersch P; Zephir H; et al. (Multiple sclerosis (Houndmills, Basingstoke, England), 2021)